Targeting long non-coding RNA to therapeutically upregulate gene expression

Research output: Contribution to journalArticle

275 Citations (Scopus)

Abstract

The majority of currently available drugs and tool compounds exhibit an inhibitory mechanism of action and there is a relative lack of pharmaceutical agents that are capable of increasing the activity of effectors or pathways for therapeutic benefit. Indeed, the upregulation of many genes, including tumour suppressors, growth factors, transcription factors and genes that are deficient in various genetic diseases, would be desired in specific situations. Recently, key roles for regulatory long non-coding RNAs (lncRNAs) in the regulation of gene expression have begun to emerge. lncRNAs can positively or negatively regulate gene expression and chromatin architecture. Here, we review the current understanding of the mechanisms of action of lncRNAs and their roles in disease, focusing on recent work in the design of inhibitors of the natural antisense transcript (NAT) class of lncRNAs, known as antagoNAT oligonucleotides, and the issues associated with their potential therapeutic application.

Original languageEnglish
Pages (from-to)433-446
Number of pages14
JournalNature Reviews Drug Discovery
Volume12
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

Long Noncoding RNA
Up-Regulation
Gene Expression
Inborn Genetic Diseases
Gene Expression Regulation
Tumor Suppressor Genes
Oligonucleotides
Pharmaceutical Preparations
Chromatin
Intercellular Signaling Peptides and Proteins
Transcription Factors
Therapeutics
Genes

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Targeting long non-coding RNA to therapeutically upregulate gene expression. / Wahlestedt, Claes R.

In: Nature Reviews Drug Discovery, Vol. 12, No. 6, 01.06.2013, p. 433-446.

Research output: Contribution to journalArticle

@article{f973c09afe7b4d88875c7e012bf161c6,
title = "Targeting long non-coding RNA to therapeutically upregulate gene expression",
abstract = "The majority of currently available drugs and tool compounds exhibit an inhibitory mechanism of action and there is a relative lack of pharmaceutical agents that are capable of increasing the activity of effectors or pathways for therapeutic benefit. Indeed, the upregulation of many genes, including tumour suppressors, growth factors, transcription factors and genes that are deficient in various genetic diseases, would be desired in specific situations. Recently, key roles for regulatory long non-coding RNAs (lncRNAs) in the regulation of gene expression have begun to emerge. lncRNAs can positively or negatively regulate gene expression and chromatin architecture. Here, we review the current understanding of the mechanisms of action of lncRNAs and their roles in disease, focusing on recent work in the design of inhibitors of the natural antisense transcript (NAT) class of lncRNAs, known as antagoNAT oligonucleotides, and the issues associated with their potential therapeutic application.",
author = "Wahlestedt, {Claes R}",
year = "2013",
month = "6",
day = "1",
doi = "10.1038/nrd4018",
language = "English",
volume = "12",
pages = "433--446",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Targeting long non-coding RNA to therapeutically upregulate gene expression

AU - Wahlestedt, Claes R

PY - 2013/6/1

Y1 - 2013/6/1

N2 - The majority of currently available drugs and tool compounds exhibit an inhibitory mechanism of action and there is a relative lack of pharmaceutical agents that are capable of increasing the activity of effectors or pathways for therapeutic benefit. Indeed, the upregulation of many genes, including tumour suppressors, growth factors, transcription factors and genes that are deficient in various genetic diseases, would be desired in specific situations. Recently, key roles for regulatory long non-coding RNAs (lncRNAs) in the regulation of gene expression have begun to emerge. lncRNAs can positively or negatively regulate gene expression and chromatin architecture. Here, we review the current understanding of the mechanisms of action of lncRNAs and their roles in disease, focusing on recent work in the design of inhibitors of the natural antisense transcript (NAT) class of lncRNAs, known as antagoNAT oligonucleotides, and the issues associated with their potential therapeutic application.

AB - The majority of currently available drugs and tool compounds exhibit an inhibitory mechanism of action and there is a relative lack of pharmaceutical agents that are capable of increasing the activity of effectors or pathways for therapeutic benefit. Indeed, the upregulation of many genes, including tumour suppressors, growth factors, transcription factors and genes that are deficient in various genetic diseases, would be desired in specific situations. Recently, key roles for regulatory long non-coding RNAs (lncRNAs) in the regulation of gene expression have begun to emerge. lncRNAs can positively or negatively regulate gene expression and chromatin architecture. Here, we review the current understanding of the mechanisms of action of lncRNAs and their roles in disease, focusing on recent work in the design of inhibitors of the natural antisense transcript (NAT) class of lncRNAs, known as antagoNAT oligonucleotides, and the issues associated with their potential therapeutic application.

UR - http://www.scopus.com/inward/record.url?scp=84880652927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880652927&partnerID=8YFLogxK

U2 - 10.1038/nrd4018

DO - 10.1038/nrd4018

M3 - Article

C2 - 23722346

AN - SCOPUS:84880652927

VL - 12

SP - 433

EP - 446

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 6

ER -